Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide

Hong-Xia Wang, Ziyuan Song, Yeh-Hsing Lao, Xin Xu, Jing Gong, Du Cheng, Syandan Chakraborty, Ji Sun Park, Mingqiang Li, Dantong Huang, Lichen Yin, Tianjian Cheng, and Kam W. Leong

Department of Biomedical Engineering, Columbia University, New York, NY 10027; Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Champaign, IL 61801; Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China; Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China; Joint International Research Laboratory of Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China; and Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou 510275, China

Edited by Shu Chien, University of California, San Diego, La Jolla, CA, and approved April 3, 2018 (received for review August 25, 2017)

Effective and safe delivery of the CRISPR/Cas9 gene-editing elements remains a challenge. Here we report the development of PEGylated nanoparticles (named P-HNPs) based on the cationic α-helical polypeptide poly(γ-(2-piperidin-1-yl)ethyl)aminomethyl)benzyl-γ-glutamate for the delivery of Cas9 expression plasmid and sgRNA to various cell types and gene-editing scenarios. The cell-penetrating α-helical polypeptide enhanced cellular uptake and promoted escape of pCas9 and/or sgRNA from the endosome and transport into the nucleus. The colloidal stable P-HNPs achieved a Cas9 transfection efficiency up to 60% and sgRNA uptake efficiency of 67.4%, representing an improvement over existing polycation-based gene delivery systems. After performing single or multiplex gene editing with an efficiency up to 47.3% in vitro, we demonstrated that P-HNPs delivering Cas9 plasmid/sgRNA targeting the polo-like kinase 1 (PLK1) gene achieved 35% gene deletion in HeLa tumor tissue by reducing the PLK1 protein level by 66.7%, thereby suppressing the tumor growth by ~71% and prolonging the animal survival rate to 60% within 60 days. Capable of delivering Cas9 plasmids to various cell types to achieve multiplex gene knock-out, gene knock-in, and gene activation in vitro and in vivo, the P-HNP system offers a versatile gene-editing platform for biological research and therapeutic applications.

Significance

Delivery remains a significant challenge for robust implementation of CRISPR/Cas9. We report an efficient CRISPR/Cas9 delivery system comprising PEGylated nanoparticles based on the α-helical polypeptide PPABLG. Assisted by the high membrane-penetrating ability of the polypeptide, P-HNPs achieved efficient cellular internalization and endosomal escape. The CRISPR/Cas9 delivery system could reach 47.3% gene editing in cells, 35% gene deletion in vivo, and HeLa tumor growth suppression >71%, demonstrating an advantage over the existing conventional polycationic transfection reagents. Efficient also in knock-in and gene activation, the reported CRISPR/Cas9 delivery system serves to advance gene editing in vitro and in vivo.

Author contributions: H.-X.W., L.Y., J.C., and K.W.L. designed research; H.-X.W., Z.S., Y.-H.L., X.K., S.C., J.S.P., M.L., and D.H. performed research; D.C. contributed new analytic tools; H.-X.W., L.Y., J.C., and K.W.L. analyzed data; and H.-X.W., Z.S., J.G., M.L., L.Y., and K.W.L. wrote the paper.

The authors declare no conflict of interest.

This open access article is distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1712963115/-/DCSupplemental.

Published online April 23, 2018.

www.pnas.org/cgi/doi/10.1073/pnas.1712963115

PNAS | May 8, 2018 | vol. 115 | no. 19 | 4903–4908
single-strand RNAs with lower charge density. Thus, nanocarriers independently optimized for the delivery of Cas9 expression plasmids and sgRNAs would be desirable.

Recently, cell-penetrating peptides (CPPs) (8), lipid-based nanoparticles (9–12), DNA nanowires (13), gold nanoparticles (14, 15), and “core-shell” artificial viruses (16) have been applied to Cas9/gRNA delivery. The CPPs, based on materials for membrane destabilization, such as HIV-TAT, GALA, and oligoarginine, have been commonly incorporated into delivery vectors for membrane destabilization to increase uptake, promote endosomal escape, and improve overall transfection efficiency (17). We hypothesize that using CPP alone as the delivery vector may be even more potent; a single-component delivery vector is also advantageous for eventual translation. However, for Cas9 expression plasmid delivery, the conventional CPPs either are too small or lack an adequate cationic charge density to function as stand-alone gene vectors. Additionally, after complexes with the nucleic acids, the overall positive charge of CPPs may be neutralized and the membrane-active domains of the short oligopeptides would be partially shielded, thus reducing their membrane activities as well as transfection efficiencies (17, 18). As such, CPPs often play only a supportive role to improve the delivery efficiencies of existing systems (17).

We previously reported the synthesis of water-soluble, α-helical polypeptides bearing a cationic side-chain terminus (19) and demonstrated the helicity-associated membrane activity that rendered these polypeptides effective gene vectors (20, 21). This type of helical polypeptide poly(γ-(1-(2-mercaptoethyl)ethyl)amine-methyl)benzyl-l-glutamate) (PPABLG) can bind and condense both plasmid DNA and short siRNA while retaining the helical structure to provide high membrane-penetrating ability for enhanced cellular internalization and endosomal escape. PPABLG can also maintain stable helical structure against changes of environmental conditions, such as pH, ionic strength, temperature, and the presence of denaturing reagents (19), making it particularly attractive for drug application. More importantly, PPABLG features high stability against proteases, a distinct advantage over the majority of CPPs that are prone to hydrolytic degradation in vivo (20, 22). The desired enzymatic stability of PPAPBLG is mainly due to its nonnatural amino acid sequences that cannot be recognized by proteases and the long hydrophobic side chains that hinder the access of proteases (19). Our previous data have also shown that this kind of helical polypeptide has superior cell-membrane permeability over HIV-TAT and Arg9 by up to two orders of magnitude and thus affords excellent DNA and siRNA delivery efficiencies in various mammalian cells (23, 24). After complexing with siRNA, the PPABLG could still maintain high membrane activities (23, 24), a desired property that short oligopeptides may not possess. PPABLG is a cationic polypeptide that can serve the dual function of an efficient gene carrier and a cell-membrane-penetrating agent. We thus hypothesized that the helical PPABLG, with high positive charge, could complex Cas9 expression plasmids and sgRNAs to form nano-complexes (referred to as helical polypeptide nanoparticles, or HNPs). To enhance the extracellular stability and the potential for in vivo application, the HNPs were PEGLyated (referred to as P-HNPs) through incorporation of PEGLyPolyhistamine40 (PEG-T40) in the formulation. We first evaluated this delivery system for multiplex gene editing in vitro (Fig. 1), followed by studying gene disruption in vivo.

### Results and Discussion

**PPAPBLG Synthesis and Nanoparticle Formulation.** The cationic, α-helical polypeptide PPAPBLG was synthesized and characterized via ring-opening polymerization of N-carboxyanhydride monomers and subsequent side-chain functionalization through ozonolysis and reductive amination (SI Appendix, Fig. S1) (20).

HNPs containing only the Cas9 expression plasmid (px165) were formulated by adding the PPAPBLG solution into the plasmid solution at various weight ratios (PPAPBLG:px165 = 1:1–15:1). The size of the polyplexes decreased from 230 nm to around 100 nm as the PPAPBLG:px165 ratio (wt/wt) increased from one to five (SI Appendix, Fig. S2A), and the zeta potential increased from 1 to above 20 correspondingly. The polydispersity index (PDI) value of HNPs at all PPAPBLG/px165 ratios was less than 0.2, indicating relatively high uniformity.

**Delivery of Cas9 Expression Plasmids into Various** Primary and Immortalized Cells. The plasmid that fuses the reporter gene GFP to the Cas9 expression cassette [pSpCas9(BB)-2A-GFP and abbreviated as px548] was used to facilitate the detection of Cas9 expression in the transfected cells. As shown in SI Appendix, Fig. S2B, HNPs formed by PPAPBLG:px548 (wt/wt = 30:1) demonstrated the best transfection efficiency (~48%) in HEK293T cells, which was comparable to the transfection efficiency of the pEGFP plasmid with dramatically smaller size (4.7 kb) (25). However, such HNPs caused ~30% cell death (SI Appendix, Fig. S2C). Moreover, HNPs were colloidally unstable in serum-containing medium (SI Appendix, Fig. S2D), which would compromise their in vivo performance. To address such an issue, we next developed P-HNPs to decrease the cytotoxicity and enhance the stability in serum (Fig. 1). Particularly, PEG-T40 was synthesized and added to the plasmid solution at various weight ratios before it was mixed with PPAPBLG. We varied the molecular weight of PEG from 2 to 5 kDa, and the PEG-T40 content in P-HNPs from 0.66% (PPAPBLG:px548:PEG-T40 = 30:10:2) to 3.22% (PPAPBLG:px548:PEG-T40 = 30:1:1). Addition of PEG-T40 did not change the size and zeta potential of the nanoparticles compared with HNPs (SI Appendix, Fig. S3 A and B), and the obtained P-HNPs with 3.22% PEG2k-T40 showed desired colloidal stability in 10% FBS-containing medium, as evidenced by inappreciable alteration of the particle (SI Appendix, Fig. S2D). As shown in SI Appendix, Fig. S3 C and D, P-HNPs modified with PEG2k-T40 at the relative content of 3.22% showed the best GFP-positive percentage and GFP mean fluorescence intensity compared with polyethylenimine (PEI) (px548 treatment or HNPs treatment. Cells treated by P-HNPs with PEG2k-T40 (1.61% PEG-T40 content) also showed a high GFP-positive percentage but were twofold lower on the GFP mean fluorescence intensity compared with HNPs modified with PEG2k-T40 at the relative content of 3.22%.

We also coated the PPAPBLG:px548 HNP complex with PEG2k-T40 by adding PEG2k-T40 after forming the PPAPBLG:px548 HNP complex [named P-HNP(coating)]. P-HNP(coating) made at the ratio of 30:1:1 (PPAPBLG:px548:PEG2k-T40) has a similar size (87 nm) and zeta potential (20.8 mV) with P-HNPs made by mixing the PEG2k-T40 with the plasmid before adding the PPAPBLG. However, P-HNP(coating) reduced the transfection efficiency to 5%...
likely caused by the masking action of PEG-T40 in blocking the cellular penetration ability of PPABLG. For all subsequent studies, we therefore settled on the formulation of mixing PEG2k-T40 with the plasmid before adding PPABLG at the ratio of 30:1:1 (PPABLG:px458:PEG2k-T40).

To evaluate the broad applicability of P-HNPs as Cas9 expression plasmid delivery vehicles, we performed plasmid transfection experiments in a variety of cell types (Fig. 2). In cancer cell lines, including HeLa and K562 cells, P-HNPs showed 32.9 and 11.0% transfection efficiency, respectively. In other immortalized cell lines, such as mouse fibroblast cells NIH 3T3 and dendritic cells DC2.4, P-HNP transfection resulted in 55.0 and 14.7% of Cas9-GFP expression, respectively. In primary cells of normal human dermal fibroblasts (NHDF) and human umbilical cord blood-derived endothelial progenitor cells (hEPCs), P-HNPs showed 24.6 and 27.7% transfection efficiency, respectively. P-HNPs for px458 plasmid transfection in all these six cell lines yielded no significant difference with HNP-based px458 plasmid transfection. Compared with Lipofectamine 3000, the most potent commercially available in vitro transfection reagent, P-HNPs performed better in the K562 cells, DC2.4 cells, NHDF cells, and hEPCs. Noteworthy is that P-HNPs lead to 1.9- to 4.9-fold higher transfection efficiency than PEI/px458 transfection, which is the most commonly used polycation gene transfection reagent (Fig. 2).

Cellular Internalization and Endosomal Escape of P-HNPs. To investigate the ability of P-HNPs to overcome cellular barriers, we assessed the cellular uptake of P-HNPs by delivering YOYO-1–labeled Cas9 expression plasmid px165. *SI Appendix, Fig. S5A,* reveals that P-HNPs had a comparable cellular uptake level with HNPs but outperformed PEI, which is consistent with the px458 plasmid transfection results (*SI Appendix, Fig. S3 C and D*). The cellular uptake for P-HNPs was inhibited by 36.1% at 4 °C, suggesting that most of the complexes enter the cell via energy-independent nonendocytosis pathways (*SI Appendix, Fig. SSB*). To investigate if the membrane permeability of PPABLG was well-maintained after forming P-HNPs, we monitored the cellular uptake of FITC–Tris, a hydrophilic membrane-impermeable fluorescent dye, in the presence of HNPs and P-HNPs (20). As shown in *SI Appendix, Fig. SSC,* P-HNPs promoted FITC–Tris uptake by ~300-ng/mg protein as well as the HNP-induced FITC–Tris uptake, suggesting that the PEGylation did not abrogate the cell-membrane–penetrating ability of P-HNP. The cellular uptake was also partially inhibited by chlorpromazine and wortmannin (*SI Appendix, Fig. SSB*), demonstrating that the clathrin-mediated pathway and macropinocytosis were involved in the endocytosis of P-HNPs. Additionally, the significant inhibition by mjCD and genistein implied that the internalization of P-HNPs was closely associated with caveolae-mediated uptake, which is beneficial for plasmid release in the cytoplasm via the bypass of lysosome formation and more direct translocation to the Golgi or endoplasmic reticulum to facilitate nuclear transport (26). Confocal laser scanning microscopy observation confirmed the endosomal escape of the P-HNPs. As shown in *SI Appendix, Fig. SSD,* in cells treated with P-HNPs as well as with HNPs, YOYO-1-labeled px165 was distributed in the whole cytoplasm and showed low colocalization with Lysotracker Red-stained endosomes. The YOYO-1–labeled px165 was also localized to the DAPI-stained nuclei in the HNP- and P-HNP–treated groups, validating that Cas9 expression plasmids could be transferred into cell nuclei to enable the Cas9 gene transcription (*SI Appendix, Fig. SSD*).

Delivery of Cas9 Plasmids and sgRNAs for in Vitro Gene Disruption and Endogenous Gene Editing. After establishing the efficiency of P-HNPs in delivering Cas9 plasmids, we also confirmed their suitability for delivering sgRNA (*SI Appendix, Fig. S5E*). The treatment by P-HNPs (30:1:1) loaded with FITC-labeled sgRNAs showed the best cellular uptake efficiency at 67.4% (*SI Appendix, Fig. SSE* and strongly outperformed PEI/sgRNA complexes (9.8%) by sevenfold and Lipofectamine 3000 (33.5%) by twofold.

The U2OS.EGFP cell line, which constitutively expresses a destabilized EGFP, was used as a model for the Cas9-induced reporter gene disruption assay. P-HNPs codelivering two plasmids expressing Cas9 and EGFP-targeting sgRNAs at the ratio of 2:1 (wt/wt for Cas9:sgRNA plasmids) produced the highest EGFP absence efficiency (29.0%) and outperformed PEI/plasmid gene disruption efficiency (7.9%) (Fig. 3A). No reduction in EGFP-positive cells was observed in control groups containing naked plasmids or Cas9 plasmid alone.

EGFP deletion was also observed when the sgRNAs were delivered in the synthetic nucleic acid format by H-NHPS instead of via transfection (*SI Appendix, Fig. S6A*). However, this only resulted in a weakened EGFP gene disruption efficiency (19.2%). Similar finding was reported by Miller et al. (27) when they used zwitter-ionic amino lipid-based nanoparticles to deliver Cas9 expression mRNAs and synthetic sgRNAs. We hypothesize that the presence of Cas9 and sgRNA in the nuclei needs to be synchronized for maximal gene editing. Observing a peak Cas9 protein at ~24 h posttransfection in our other experiments, we delivered the synthetic sgRNAs 24 h after the Cas9 plasmid transfection and did observe a higher EGFP disruption efficiency at 35.7% (Fig. 3B and C). The lower performance of the HNP group (24.9%) and the PEI treatment group (8.2%) appeared to be related to the poorer cellular uptake of the sgRNA nanoparticles (*SI Appendix, Fig. S5E*).
We also compared the EGFP disruption efficiency of P-HNPs with the commercial formulations Lipofectamine 2000, Lipofectamine 3000, and Lipofectamine CRISPRMAX. Although the Lipofectamine CRISPRMAX could induce a higher gene disruption (51.2%) compared with P-HNPs (36.5%), the delivery of Cas9 proteins may face concerns such as affordability, purity of the Cas9 protein, and nonspecific nuclease action-mediated toxicity, especially humoral immunity to Cas9 (28). In direct comparison with Lipofectamine 2000 and 3000 in Cas9 plasmid and sgRNA delivery, P-HNPs outperformed Lipofectamine 2000 and were comparable to Lipofectamine 3000 in U2OS.EGFP cells. To verify that the EGFP disruption arose from insertion-deletion (indel) events, we applied the genome cleavage detection (GCD) assay to quantify the frequency of indels at the target EGFP locus (Fig. 3B). We observed 30.7, 22.5, and 6.2% indels for the P-HNP, HNP, and PEI treatment, respectively, which supported the results of flow cytometry analysis (Fig. 3B and C). The indel frequencies at EGFP-target sites in cells treated by P-HNPs were also assayed by DNA sequencing (SI Appendix, Fig. S6C). The sequencing of 21 clones showed 8 clones with mutations near the target site, confirming that the gene disruption was mediated by the CRISPR/Cas9 system. The GCD disruption efficiency of the P-HNP delivery system was comparable with the self-assembled DNA Nanoclew for the Cas9 protein/sgRNA complex in the same cell line (13).

A major concern in using the CRISPR/Cas9 for genome engineering is the off-target editing. Using the GCD assay to detect the indels at two off-target sites for the EGFP-targeting sgRNA, we observed a lower off-target cleavage (<2.8%) in cells treated by sequentially delivering the Cas9 expression plasmid and the synthetic sgRNAs (SI Appendix, Fig. S6D), compared with lipids or short CPP-mediated Cas9 plasmid delivery if differences in the targeted gene and sequence were neglected (8, 29).

After validating the reporter gene disruption in a model cell line, we evaluated the genome editing of endogenous genes in HEK293T cells. Noting the potential biomedical relevance of editing the adeno-associated virus integration site 1 (AAVS1) gene (30) and the hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene (31), we evaluated the transfection of P-HNPs loaded with Cas9 expression plasmids and sgRNA targeting AAVS1 or HPRT1. The disruption efficiencies of 42.5% for the AAVS1 gene and 46.0% for the HPRT1 gene (31), we evaluated the transfection of P-HNPs loaded with Cas9 expression plasmids and the synthetic sgRNAs and HDR donor after selection with puromycin for 2 wk. The AAVS1 gene (30) and the hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene were targeted by the CRISPR/Cas9 system. The GCD disruption efficiency of the P-HNP delivery system was comparable with the self-assembled DNA Nanoclew for the Cas9 plasmid and sgRNA complex in the same cell line (13).
offering an immense potential for biological and therapeutic applications. To investigate whether the P-HNP system could attain gene insertion by homology-directed repair (HDR), we first delivered the Cas9 expression plasmid, followed by the delivery of AAVS1 targeting sgRNAs and the HDR donor template 24 h later using the same P-HNP carrier (Fig. 4A). The GFP and puromycin expression sequences were involved in the HDR donor template. Three days after transfection, the HDR events were verified by PCR using a forward primer recognizing the AAVS1 genome and a reverse primer binding to the puromycin gene in the donor template (Fig. 4A and SI Appendix, Table S1). PCR assay demonstrated that only cells treated with the delivery of Cas9 expression plasmids, sgRNAs, and HDR donor templates exhibited HDR events (Fig. 4B). Cells treated with nanoparticles delivering sgRNA and donor only, without Cas9 expression plasmid, did not show any PCR product. This result demonstrated that the increased HDR events were initiated by CRISPR/Cas9 cleavage, not by traditional HDR events. Although both the transfection of PEI complexes and HNPs showed HDR events, the PCR products of P-HNP transfection were more intense. Several clones with strong GFP expression were formed after selection with puromycin for 2 wk (Fig. 4C). The HDR event was also confirmed by Sanger sequencing of the selected clone’s genome and detection of the expected DNA bases at the genome-donor boundary (Fig. 4D).

Delivery of dCas9 Plasmids and sgRNA for in Vitro Gene Activation. The CRISPR/Cas9 technology can also be applied to activate gene expression by introduction of point mutations into the Cas9 nuclease domain to generate a deactivated Cas9 (dCas9) and then by fusing a transactivator such as VP64 to dCas9 (32, 33). We tested the delivery efficiency of the pMax-VP64-dCas9-BFP-V5 plasmid of PEI, HNP, and P-HNP. The design of pMax-VP64-dCas9-BFP-V5 is such that the dCas9 is fused to two transactivation VP64 domains for higher activation and a BFP protein for ease of detection and optimization (32, 33). P-HNP transfection on NIH 3T3 cells resulted in 41.5% BFP expression, with no significant difference compared with HNP transfection transfection on NIH 3T3 cells resulted in 41.5% BFP expression, with no significant difference compared with HNP transfection. We tested the delivery efficiency of the pMax-VP64-dCas9-BFP-V5 plasmid of PEI, HNP, and P-HNP. The design of pMax-VP64-dCas9-BFP-V5 is such that the dCas9 is fused to two transactivation VP64 domains for higher activation and a BFP protein for ease of detection and optimization (32, 33). P-HNP transfection on NIH 3T3 cells resulted in 41.5% BFP expression, with no significant difference compared with HNP transfection. We tested the delivery efficiency of the pMax-VP64-dCas9-BFP-V5 plasmid of PEI, HNP, and P-HNP. The design of pMax-VP64-dCas9-BFP-V5 is such that the dCas9 is fused to two transactivation VP64 domains for higher activation and a BFP protein for ease of detection and optimization (32, 33). P-HNP transfection on NIH 3T3 cells resulted in 41.5% BFP expression, with no significant difference compared with HNP transfection. We tested the delivery efficiency of the pMax-VP64-dCas9-BFP-V5 plasmid of PEI, HNP, and P-HNP. The design of pMax-VP64-dCas9-BFP-V5 is such that the dCas9 is fused to two transactivation VP64 domains for higher activation and a BFP protein for ease of detection and optimization (32, 33). P-HNP transfection on NIH 3T3 cells resulted in 41.5% BFP expression, with no significant difference compared with HNP transfection. We tested the delivery efficiency of the pMax-VP64-dCas9-BFP-V5 plasmid of PEI, HNP, and P-HNP. The design of pMax-VP64-dCas9-BFP-V5 is such that the dCas9 is fused to two transactivation VP64 domains for higher activation and a BFP protein for ease of detection and optimization (32, 33). P-HNP transfection on NIH 3T3 cells resulted in 41.5% BFP expression, with no significant difference compared with HNP transfection.
achieved significant tumor inhibition in comparison with PBS, free Cas9 plasmid/free sgPk1, and P-HNP+Cas9, leading to a tumor suppression of >71% (Fig. 5C). Accordingly, P-HNP+PCas9+sgPlk1 notably improved the survival rate of mice to 60% (Fig. 5D). The body weight of mice did not change noticeably compared with the control group, suggesting low toxicity of P-HNPs (SI Appendix, Fig. S7D). In consistency with the antitumor efficacy, P-HNPPCas9+sgPlk1 led to remarkable cancer cell necrosis in hematoxylin and eosin (H&E)-stained tumor tissues and afforded the highest cell re- mission level in tumor tissue sections immune-stained with EdU-U- 594 (SI Appendix, Fig. S7E). To further confirm the CRISPR/Cas9-mediated in vivo gene editing of Plk1, the indel frequency at the Plk1 locus in tumor tissues following P-HNPPCas9+sgPlk1 treatment was measured by deep sequencing. Among the se- quenced 20 clones, 7 clones had mutations near the target site, at the Plk1 locus in tumor tissues following P-HNP+PCas9+sgPlk1 treatment was measured by deep sequencing. Among the se- quenced 20 clones, 7 clones had mutations near the target site, suggesting the applicability of P-HNPs for local in vivo CRISPR/Cas9 gene editing toward anticancer therapy, its potential results suggest the applicability of P-HNPs for local in vivo CRISPR/Cas9 gene editing toward anticancer therapy, its potential for systemic application remains a subject of ongoing investigation. Work is in progress to modify the synthesized sgRNAs for higher stability, to understand the biodistribution via different administra- tion routes, and to evaluate the targeting ability of this delivery system for various gene-editing applications in vivo.

Conclusions. In this work, we reported the synthesis and applica- tion of a PEGylated nanoparticle, P-HNP, based on the cationic α-helical polypeptide PPABLG and Cas9 expression plasmid/ sgRNAs for genome editing in mammalian cells and in tumor tissue. The P-HNPs showed high membrane-penetrating ability to facilitate cell uptake, escape from the endosome, and translocate into the nucleus for CRISPR/Cas9-based genome editing. The P- HNPs efficiently delivered Cas9 plasmid or sgRNA, as a complex or separately, to various cell types including tumor cells, fibro- blasts, dendritic cells, and human endothelial progenitor cells to achieve multiplex gene knockout, demonstrating an advantage over the existing polycation-based gene vectors. P-HNPs could also mediate gene knock-in and gene activation. In vivo studies further indicated the efficiency of this nonviral gene-editing sys- tem for topical anticancer therapy. Given the potency of PPABLG for systemic siRNA delivery in vivo, this work suggests the broad potential of P-HNPs for nonviral gene editing.

Materials and Methods

Detailed materials and methods are provided in SI Appendix, including the synthesis of PPABLG and PEG-Tao, preparation and characterization of HNPs and P-HNPs, and delivery of plasmids and sgRNAs in vitro and in vivo.

ACKNOWLEDGMENTS. We thank Prof. J. Keith Joung (Massachusetts General Hospital) for providing the U2OS.EGFP cell line and Prof. Jun Wang and Prof. Yucai Wang (University of Science and Technology of China) for providing the AS49.GFP cell line. Funding support was received from the NIH (Grants HL134622, AUD3605, GM110494, and U54 TR000020); National Natural Science Foundation of China (Grants 51575323 and 51722030); the Ministry of Science and Technology of China (Grant 2016YFA0102100); Guangdong Innovative and Entrepreneurial Research Team Program (Grant 2013B080071974), and Global Research Laboratory Program (Korean NSF GRL; 201303163).